Compare TLIH & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLIH | ADXN |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | Singapore | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 10.3M |
| IPO Year | 2025 | N/A |
| Metric | TLIH | ADXN |
|---|---|---|
| Price | $0.39 | $7.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 691.4K | 9.0K |
| Earning Date | 09-30-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $51,204,304.00 | $198,824.00 |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.51 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.31 | $6.51 |
| 52 Week High | $7.00 | $12.05 |
| Indicator | TLIH | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 41.05 | 45.80 |
| Support Level | $0.39 | $7.60 |
| Resistance Level | $0.67 | $8.00 |
| Average True Range (ATR) | 0.07 | 0.38 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 2.31 | 44.56 |
Ten-League International Holdings Ltd is a Singapore-based provider of turnkey project solutions. Its business consists of sales of heavy equipment and parts, heavy equipment rental and provision of engineering consultancy services to port, construction, civil engineering and underground foundation industries. It currently conducts its operations through its wholly-owned subsidiaries. The equipment it provides is organized into four categories based on their functions and application scenarios, namely, foundation equipment, hoist equipment, excavation equipment and port machinery. The company operates in Singapore and Other International Countries.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.